TP53 and acute myeloid leukemia: Importantly, TP53 alterations, that occur in around 8% of all AML patients and in 70% of patients with AML and complex karyotype, are associated to very bad prognosis [5, 6] and have a relevant role in the origin and evolution of therapy-related AML [7].